All articles by Manasi Vaidya
Manasi Vaidya is the lead editor for Pharmaceutical Technology where she covers the healthcare space. She writes features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science. She is based in Brooklyn and an alum of New York University’s Science, Health and Environmental Reporting program.
Manasi Vaidya
@manasivaidya22
Looking back at 2022: The top healthcare stories
We revisit some of our top stories of 2022, and the news and trends that shaped the healthcare sector this year.
Russia sanctions: what next for Sputnik Covid-19 vaccine production around the world?
The Russian invasion of Ukraine has knock-on effects on the Covid-19 pandemic as supplies of Sputnik V vaccine to Asian, African, and South American countries are now in question.
Clinical trial diversity: It’s time to quit talking and start doing
In order to improve diversity in trials, inequities due to economic factors and race need to be bridged at institutional levels.
Trial diversity-it’s time to quit talking and start doing
In order to improve diversity in trials, inequities due to economic factors and race need to be bridged at institutional levels
Most of Latin America, Caribbean left behind in Merck’s oral Covid-19 antiviral deal
Many upper middle-income countries fall between the cracks after a recent landmark contract opened molnupiravir access to 105 countries.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Coverage restrictions likely to apply to recently-approved ANCA vasculitis drug
Payers will likely use restrictions seen with other rare diseases when it comes to ChemoCentryx’s recently approved AAV drug.
Merck’s molnupiravir: Covid-19 gamechanger status relies on patient risk factors
Molnupiravir access may depend on how risk factors are interpreted but availability could be wider with the help of pharmacists
Quest persists for ideal Covid-19 booster timelines, vaccine mixing in blood cancers
While the FDA contemplates Covid-19 booster use, researchers have begun investigating their activity in blood cancer patients.
Uneven Covid-19 vaccine efficacy in blood cancers mean masks to stay
A quarter of haematological cancer patients do not mount an effective immune response after Covid-19 vaccination.
RSV vaccines improve on technology but contend with a post-Covid world
Post-Covid changes including social distancing measures and seasonal shifts have challenged RSV vaccine development projects.